11. Feb 2021 |
2 min read
Moss, 11 February 2020Gentian Diagnostics AS announces its results for the 4th quarter and 2020preliminary annual results. The highlights include:* Gentian finished the year with record sales of MNOK 17.2 in the 4Q20 whichcorresponds to 22 % growth versus 4Q19* Total sales revenue for the year was MNOK 63.3 representing a 32 % growth (22% adjusted for currency effects) compared to the same period last year* Double digit sales growth was achieved for all products and all regions in2020* Gentian’s unique PETIA-based SARS-CoV-2 antibody test has reached the nextdevelopment phase with an estimated launch by the end of 2021* Encouraging scientific publications on GCAL® in context of COVID-19 patientmanagement have spurred the interest of hospitals and laboratories from all overEuropePlease find the report and results presentation enclosed. The documents willalso be made available on www.gentian.com.
524428_GDAS Interim presentation 4Q 2020
524428_GDAS Interim Report 4Q 2020For further information, please contact:Hilja IbertCEO, Gentian DiagnosticsE-mail: email@example.com Cell Phone: +47 919 05 242Njaal KindCFO, Gentian DiagnosticsE-mail: firstname.lastname@example.org Cell Phone. +47 919 06 525
More information:Access the news on Oslo Bors NewsWeb site
Feb 11, 2021 - Kristin Hart
Moss, 11 February 2020 Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary..
Feb 05, 2021 - Kristin Hart
Moss, 05 FEB 2021
Jan 22, 2021 - Kristin Hart
Moss, 22.01.2021 Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody..